# Developmental Funds

> **NIH NIH P30** · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · 2024 · $204,199

## Abstract

Abstract Developmental Funds (DF)
The overall goal of the Developmental Funds of the City of Hope Comprehensive Cancer Center (COHCCC) is
to stimulate innovative early-stage research that addresses cancer prevention, diagnostics, treatment or health
disparities. Developmental Funds awards provide COHCCC investigators with seed money for generating
preliminary data and/or support for multi-project grant applications, enabling them to successfully apply for
independent peer-reviewed funding. Developmental Funds also support clinical Early-Stage Investigators (ESI)
by granting them additional protected time for developing their first NCI grant or investigator-initiated clinical trial.
We foster diversity in our research teams by specifically providing pilot awards to investigators from groups that
are underrepresented in biomedical research. We also aspire to improve diversity of the patients enrolled in our
clinical trials by supporting clinical ESI for developing trials that will increase accrual of patient URGs and/or to
be conducted at our clinical network sites. In addition to mechanism-specific eligibility, awards prioritize inter-
program and multi-disciplinary collaborations, as well as alignment with COHCCC strategic priorities.
Developmental Funds stimulate the production of high-quality research proposals via the following Specific Aims:
 Aim 1. Support innovative pilot projects from diverse investigators and multi-disciplinary teams
 Aim 2. Provide protected research time for early-career physician scientists with Clinical ESI Awards
Dr. Larry Kwak, as COHCCC Deputy Director, oversees Developmental Funds, providing strategic direction and
overall leadership and ensuring that Developmental Funds activities leverage opportunities across the COH
enterprise. While Dr. Kwak oversees the scientific aspects of Developmental Funds, the Associate Director of
Administration, Ashley Baker Lee, is responsible for managing the awards in keeping with NCI guidelines and
best practices, including announcements, scientific review facilitation, pre/post award management and impact
metrics through the COHCCC Administration. The scientific merit and mission alignment of award applications
will be evaluated by the Scientific Review Committee, with standing members consisting of Drs. Kwak and
Rosen, a biostatistician, one member from each COHCCC Program, and at least one basic, one translational
and one clinical scientist. Funding decisions will be made by majority vote and ranking of proposals, with
borderline cases decided by Drs. Rosen and Kwak.
In the current funding cycle (2017-2021), CCSG funds supported the development of a new SR, now a full SR,
known as the Population-Facing Research Shared Resource (PFR-SR) that is widely used by Cancer Center
members. PFR-SR facilitated 21 NIH grants (7 multi-PI) and PFR-SR services generated 36 publications.
COHCCC also distributed 4 Team Science Awards that resulted in the submission of 2 NCI SPORE and 2 NCI
Prog...

## Key facts

- **NIH application ID:** 10843124
- **Project number:** 5P30CA033572-41
- **Recipient organization:** BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
- **Principal Investigator:** LARRY W KWAK
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $204,199
- **Award type:** 5
- **Project period:** 1997-08-01 → 2027-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10843124

## Citation

> US National Institutes of Health, RePORTER application 10843124, Developmental Funds (5P30CA033572-41). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10843124. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*